Viewing Study NCT04274933


Ignite Creation Date: 2025-12-25 @ 2:59 AM
Ignite Modification Date: 2026-01-09 @ 6:07 PM
Study NCT ID: NCT04274933
Status: TERMINATED
Last Update Posted: 2020-10-29
First Post: 2020-02-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
Sponsor: AbbVie
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Cancer View
None Metastatic View
None Locally Advanced View
None Venetoclax View
None Capecitabine View
None Hormone Receptor Positive View
None HER2 Negative View